Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2014

View Archived Issues

Shionogi updates developments of third quarter of fiscal 2013

Roche reviews recent highlights of fourth quarter 2013

Discovery of a novel IAP antagonist with clinical potential for the treatment of cancer

Swiss group presents novel agents for cancer and other disorders

MacroGenics achieves milestone under agreement with Servier for MGD-006

Janssen Pharmaceutica synthesizes new CCR2 receptor antagonists

Merck & Co. collaborates with Amgen, Incyte and Pfizer to study new anticancer regimens

Second-generation proteasome inhibitors could be repurposed as antivirals

Novo Nordisk returns full rights for IPH-2201 to Innate Pharma

Researchers detail design of MPS1 inhibitor CCT-251455

Researchers report novel method of somatic cell reprogramming into bidirectional pluripotent cells

TG-01 enters phase IIa trial in operable pancreatic cancer

Audentes and Genethon enter agreement to develop gene therapy for X-linked myotubular myopathy

Novartis patents novel complement factor D inhibitors

Scientists at Euclises Pharmaceuticals disclose novel antitumor agents

Infectex acquires exclusive rights to Qurient's tuberculosis drug

Argos Therapeutics presents update on the phase III ADAPT trial evaluating AGS-003

Navidea reports initial results from phase IIb trial of its beta-amyloid imaging agent NAV-4694

Shire decides to discontinue development of Vyvanse capsules for major depressive disorder

ProMetic enters new development agreement with vaccines company

REGiMMUNE initiates phase II trial of RGI-2001 for graft versus host disease

FDA accepts NDA filing for Beleodaq

Trigemina expands phase II study of intranasal oxytocin candidate for chronic migraine

Roche reports development of novel cell penetrating peptides for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...